Please ensure Javascript is enabled for purposes of website accessibility

Moderna and Other Coronavirus Vaccine Developers to Testify in Congress July 21

By Eric Volkman – Jul 11, 2020 at 10:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AstraZeneca, Johnson & Johnson, Merck, and Pfizer will also field questions from lawmakers.

Moderna (MRNA 0.15%) has a date with Congress. The House Committee on Energy and Commerce has called for it to testify in front of its members, along with four other companies currently developing coronavirus vaccines. Those four are AstraZeneca (AZN -0.13%), Johnson & Johnson (JNJ -0.71%), Merck (MRK -0.60%), and Pfizer (PFE -0.91%).

Officials from those companies will field questions from the committee's oversight and investigations subcommittee on the current state of their vaccine development processes.

In its official announcement, the committee said that "[w]e look forward to hearing from each of the companies about their research and development efforts, safety and efficacy standards and their ongoing preparations to manufacture and distribute an eventual vaccine."

A researcher studying a sample in a petri dish.

Image source: Getty Images.

The committee promised that additional details about the hearings, which are scheduled for Tuesday, July 21, will be provided the week before they take place.

Moderna, AstraZeneca, Johnson & Johnson, Merck, and Pfizer are not the only biotechs or pharmaceutical companies developing vaccine candidates. However, they are the five tapped to participate in the government's Warp Speed program, in which it's contributing resources to helping the most promising vaccine candidates through the development process.

Of the quintet, Moderna is considered by many to be the frontrunner in the race. Its mRNA-1273 candidate is currently undergoing a phase 2 trial; meanwhile, the company is scheduled to begin phase 3 testing simultaneously by the end of this month. Allegedly, friction between company and government health officials has resulted in delays, but Moderna continues to pledge a July start date.

Interestingly, Moderna was the group's worst-performing stock on Friday -- it fell by 3.6%. AstraZeneca and Johnson & Johnson dropped on the day, while Merck inched slightly higher. The only company that beat the gains of the wider stock market was Pfizer, which rose 1.1%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$118.25 (0.15%) $0.18
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.12 (-0.60%) $0.52
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$163.36 (-0.71%) $-1.17
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.84 (-0.13%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.